Literature DB >> 16571607

Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood.

C A Lawson1, A K Brown, V Bejarano, S H Douglas, C H Burgoyne, A S Greenstein, A W Boylston, P Emery, F Ponchel, J D Isaacs.   

Abstract

OBJECTIVE: Our aim was to test the hypothesis that there is a deficit in the CD4+CD25high regulatory T-cell population in early rheumatoid arthritis (RA), either in size or functional activity.
METHODS: Peripheral blood mononuclear cells were examined from subjects with early active RA who had received no previous disease-modifying therapy (n = 43), from individuals with self-limiting reactive arthritis (n = 14), from subjects with stable, well-controlled RA (n = 82) and from healthy controls (n = 72). The frequencies of CD4+CD25high T-cells were quantified using flow cytometry, and function was assessed by the ability to suppress proliferation of CD4+CD25- T-cells. Paired blood and synovial fluid was analysed from a small number of RA and reactive arthritis patients.
RESULTS: There was a smaller proportion of CD4+CD25high T-cells in the peripheral blood of early active RA patients (mean 4.25%) than in patients with reactive arthritis or in controls (mean 5.90 and 5.30%, respectively, P = 0.001 in each case). Frequencies in stable, well-controlled RA (mean 4.63%) were not significantly different from early active RA or controls. There were no differences in suppressor function between groups. Higher frequencies of CD4+CD25high T-cells were found in synovial fluid than blood in both RA and reactive arthritis.
CONCLUSIONS: These data demonstrate a smaller CD4+CD25high regulatory T-cell population in peripheral blood of individuals with early active RA prior to disease-modifying treatment. This may be a contributory factor in the susceptibility to RA and suggests novel approaches to therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571607     DOI: 10.1093/rheumatology/kel089

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  71 in total

1.  B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis.

Authors:  Keith M Hamel; Yanxia Cao; Susan Ashaye; Yumei Wang; Robert Dunn; Marilyn R Kehry; Tibor T Glant; Alison Finnegan
Journal:  J Immunol       Date:  2011-09-23       Impact factor: 5.422

2.  Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis.

Authors:  Shiqian Shen; Junghee J Shin; Klemen Strle; Gail McHugh; Xin Li; Lisa J Glickstein; Elise E Drouin; Allen C Steere
Journal:  Arthritis Rheum       Date:  2010-07

3.  Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response.

Authors:  Rossella Talotta; Angela Berzi; Fabiola Atzeni; Alberto Batticciotto; Mario Clerici; Piercarlo Sarzi-Puttini; Daria Trabattoni
Journal:  J Clin Immunol       Date:  2015-08-14       Impact factor: 8.317

Review 4.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

Review 5.  The role of CD4+CD25+ T regulatory cells in autoimmune diseases.

Authors:  E Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 6.  Regulatory T cells in rheumatoid arthritis.

Authors:  Sujata Sarkar; David A Fox
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

Review 7.  Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Authors:  Jonathan H Esensten; David Wofsy; Jeffrey A Bluestone
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

8.  Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.

Authors:  Maura Rossetti; Roberto Spreafico; Suzan Saidin; Camillus Chua; Maryam Moshref; Jing Yao Leong; York Kiat Tan; Julian Thumboo; Jorg van Loosdregt; Salvatore Albani
Journal:  J Immunol       Date:  2014-12-01       Impact factor: 5.422

Review 9.  Emerging cell and cytokine targets in rheumatoid arthritis.

Authors:  Gerd R Burmester; Eugen Feist; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

Review 10.  Lymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?

Authors:  Kristina Schreiber; Gaetane Nocturne; Divi Cornec; Claire I Daïen
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.